Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy.
Animals
B-Lymphocytes
/ drug effects
Drug Resistance, Neoplasm
/ drug effects
Humans
Immune Checkpoint Inhibitors
/ pharmacology
Lymphocytes, Tumor-Infiltrating
/ drug effects
Mast Cells
/ drug effects
Melanoma
/ immunology
Mice, Transgenic
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Sunitinib
/ pharmacology
T-Lymphocytes
/ drug effects
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
12 01 2021
12 01 2021
Historique:
received:
16
04
2020
accepted:
10
12
2020
entrez:
13
1
2021
pubmed:
14
1
2021
medline:
22
1
2021
Statut:
epublish
Résumé
Anti-PD-1 therapy is used as a front-line treatment for many cancers, but mechanistic insight into this therapy resistance is still lacking. Here we generate a humanized (Hu)-mouse melanoma model by injecting fetal liver-derived CD34
Identifiants
pubmed: 33436641
doi: 10.1038/s41467-020-20600-7
pii: 10.1038/s41467-020-20600-7
pmc: PMC7804257
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Programmed Cell Death 1 Receptor
0
Sunitinib
V99T50803M
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
346Subventions
Organisme : NCI NIH HHS
ID : R01 CA165065
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA140043
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA010815
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA114046
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA211199
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA174523
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA224070
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Cell. 2017 Nov 2;171(4):934-949.e16
pubmed: 29033130
Nat Biotechnol. 2014 Apr;32(4):364-72
pubmed: 24633240
Cell Metab. 2019 Mar 5;29(3):769-783.e4
pubmed: 30713110
Mol Ther. 2014 Jan;22(1):42-51
pubmed: 24077034
Cancer Immunol Res. 2019 Jun;7(6):1025-1035
pubmed: 31043414
Cancer Res. 2005 Oct 15;65(20):9328-37
pubmed: 16230395
J Infect Dis. 2013 Nov;208 Suppl 2:S125-30
pubmed: 24151318
Methods Mol Biol. 2018;1711:243-259
pubmed: 29344893
Semin Cancer Biol. 2009 Apr;19(2):92-6
pubmed: 19049876
FASEB J. 2018 Mar;32(3):1537-1549
pubmed: 29146734
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Nat Commun. 2017 Sep 19;8(1):592
pubmed: 28928380
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Mol Pharm. 2011 Dec 5;8(6):2039-49
pubmed: 22067046
Genome Biol. 2014;15(12):550
pubmed: 25516281
Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2842-5
pubmed: 8464898
Immunohorizons. 2020 Aug 20;4(8):508-519
pubmed: 32819967
Nature. 2017 Jul 6;547(7661):94-98
pubmed: 28636589
Exp Dermatol. 2017 Jan;26(1):11-17
pubmed: 27305467
Cancer Growth Metastasis. 2015 Oct 06;8(Suppl 1):81-94
pubmed: 26483610
Clin Cancer Res. 2018 Oct 15;24(20):4960-4967
pubmed: 29685882
Clin Cancer Res. 2008 Oct 15;14(20):6674-82
pubmed: 18927310
Nature. 2018 Aug;560(7718):382-386
pubmed: 30089911
Clin Cancer Res. 2019 Sep 1;25(17):5191-5201
pubmed: 30923036
Bioinformatics. 2015 Sep 15;31(18):2963-71
pubmed: 25987567
Annu Rev Pathol. 2017 Jan 24;12:187-215
pubmed: 27959627
Clin Cancer Res. 2009 Mar 15;15(6):2148-57
pubmed: 19276286
Br J Cancer. 2018 Jan;118(1):9-16
pubmed: 29319049
Oncoimmunology. 2015 Nov 5;5(3):e1083670
pubmed: 27141336
Am J Pathol. 2010 Aug;177(2):1031-41
pubmed: 20616342
Nat Med. 2019 Mar;25(3):454-461
pubmed: 30804515
Front Immunol. 2017 Apr 12;8:424
pubmed: 28446910
Nat Commun. 2017 Sep 19;8(1):607
pubmed: 28928360
Nature. 2017 May 4;545(7652):60-65
pubmed: 28397821
Br J Cancer. 2015 Jul 14;113(2):327-35
pubmed: 26042934
Am Soc Clin Oncol Educ Book. 2019 Jan;39:147-164
pubmed: 31099674
Trends Cancer. 2020 May;6(5):432-441
pubmed: 32348738
Front Oncol. 2018 Mar 28;8:86
pubmed: 29644214
Invest New Drugs. 2019 Dec;37(6):1198-1206
pubmed: 30725388
Oncoimmunology. 2017 Mar 7;6(8):e1299303
pubmed: 28919986
Infect Immun. 2016 Aug 19;84(9):2449-62
pubmed: 27297390
Phys Med Biol. 2019 Jan 16;64(2):025017
pubmed: 30561383
J Immunol. 2014 Mar 15;192(6):2892-903
pubmed: 24523508
Clin Cancer Res. 2015 Apr 1;21(7):1652-64
pubmed: 25617424
Front Med (Lausanne). 2018 Sep 25;5:271
pubmed: 30320116
Front Immunol. 2018 Jun 08;9:1305
pubmed: 29937769